Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
After finishing at $24.85 in the prior trading day, Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) closed at $25.38, up 2.13%. In other words, the price has increased by $2.13 from its previous closing price. On the day, 0.88 million shares were traded. CNTA stock price reached its highest trading level at $25.7 during the session, while it also had its lowest trading level at $24.87.
Ratios:
Our goal is to gain a better understanding of CNTA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.57 and its Current Ratio is at 10.57. In the meantime, Its Debt-to-Equity ratio is 0.39 whereas as Long-Term Debt/Eq ratio is at 0.39.
On October 28, 2025, Stephens started tracking the stock assigning a Overweight rating and target price of $35.
On September 03, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $31.Wells Fargo initiated its Overweight rating on September 03, 2025, with a $31 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 09 ’25 when Accardi Mario Alberto sold 10,000 shares for $28.83 per share. The transaction valued at 288,289 led to the insider holds 178,801 shares of the business.
Accardi Mario Alberto bought 10,000 shares of CNTA for $293,000 on Dec 09 ’25. On Dec 08 ’25, another insider, Accardi Mario Alberto, who serves as the President, Orexin Program of the company, sold 10,000 shares for $30.00 each. As a result, the insider received 300,000 and left with 188,801 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CNTA now has a Market Capitalization of 3707402240 and an Enterprise Value of 3284331008. For the stock, the TTM Price-to-Sale (P/S) ratio is 226.53 while its Price-to-Book (P/B) ratio in mrq is 11.31. Its current Enterprise Value per Revenue stands at 218.955 whereas that against EBITDA is -15.384.
Stock Price History:
The Beta on a monthly basis for CNTA is 1.57, which has changed by 0.47041416 over the last 52 weeks, in comparison to a change of 0.13153219 over the same period for the S&P500. Over the past 52 weeks, CNTA has reached a high of $30.58, while it has fallen to a 52-week low of $9.60. The 50-Day Moving Average of the stock is -1.46%, while the 200-Day Moving Average is calculated to be 39.08%.
Shares Statistics:
The stock has traded on average 1.55M shares per day over the past 3-months and 1573880 shares per day over the last 10 days, according to various share statistics. A total of 134.42M shares are outstanding, with a floating share count of 88.33M. Insiders hold about 34.29% of the company’s shares, while institutions hold 59.89% stake in the company. Shares short for CNTA as of 1764288000 were 6077982 with a Short Ratio of 3.91, compared to 1761868800 on 5153546. Therefore, it implies a Short% of Shares Outstanding of 6077982 and a Short% of Float of 4.760000000000001.
Earnings Estimates
The stock of Centessa Pharmaceuticals plc ADR (CNTA) is currently in the spotlight, with 9.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.41, with high estimates of -$0.38 and low estimates of -$0.47.
Analysts are recommending an EPS of between -$1.05 and -$1.42 for the fiscal current year, implying an average EPS of -$1.34. EPS for the following year is -$1.62, with 10.0 analysts recommending between -$1.24 and -$2.02.
